Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
December 14, 2016
- Diet members Aim to Create Non-Partisan Forum for Healthcare Industry
December 14, 2016
- Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
December 14, 2016
- LDP Health Panel Chair Submits Letter Opposing Annual Price Revisions
December 13, 2016
- PMDA Reviewing Risk of Hep B Virus Reactivation for Revlimid
December 13, 2016
- MHLW Announces 16 APIs as Candidates for Switch-OTC Status: None for Lifestyle Diseases
December 13, 2016
- MHLW Panel Recommends 3 Products Including Talion for Approval as “Behind-the-Counter Drugs”
December 13, 2016
- Balance between Survey Costs and Price Gap Important, Shiozaki Says on Annual Revisions
December 12, 2016
- HIV Med Descovy Approved in Japan
December 12, 2016
- Industry Casts Doubt on “1.25 Times” Threshold for Downward Tweak under Foreign Price Adjustment Rule
December 12, 2016
- Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
- Health Minister Calls for Structural Change in Pharma Industry
December 12, 2016
- The Sooner the Better, Suga Says on Drug Pricing Revamp
December 12, 2016
- Industry’s “No” to Disclosure of Manufacturing Costs Draws Fire from Chuikyo Reps
December 12, 2016
- (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
December 12, 2016
- Shiozaki Will Bring Chuikyo’s Views to 4-Way Confab, No Paper Planned: Official
December 12, 2016
- (Update) Pharma Trade Groups Express Strong Opposition to Annual Price Revisions: Chuikyo
December 12, 2016
- Ruling Parties Compile FY2017 Tax Reform Package, R&D Tax Credit Revamp Specified
December 9, 2016
- Healthcare-Related LDP Legislators Criticize Annual Revisions
December 9, 2016
- Govt Eyes “Bailout Measures” for Products with Small NHI-Market Price Gaps in Annual Revision Plan
December 9, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…